Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Serono Increases Oncology Medical Representatives To Expand Japanese Market

This article was originally published in PharmAsia News

Executive Summary

With the recent market launch of colon cancer drug Erbitux (cetuximab), German drug maker Merck Serono plans to add 20 to 40 oncology medical representatives in three years in Japan. Merck Serono currently has 60 oncology MRs in Japan. Merck Serono's president estimated that as colon cancer will likely top cancer cases in Japan by 2020, Erbitux could become a blockbuster drug. (Click here for more - Japanese language

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts